Immunotherapy in Lung Cancer | Specialty

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

PD-1/CTLA-4 Combos, Broader Patient Population Are Next Steps With Immunotherapy in Locally Advanced NSCLC

October 12th 2020

David Gerber, MD, highlights the impact of the PACIFIC trial and other next steps with immunotherapy in patients with stage III NSCLC.

Next Steps in Small Cell Lung Cancer Feature Closer Eye on Immunotherapy, Lurbinectedin

October 8th 2020

Benjamin Drapkin, MD, PhD, discusses the road ahead in small cell lung cancer research, and the challenges that still need to be solved in the first- and second-line settings.

PD-1 Inhibition Reigns Supreme in Advanced Squamous NSCLC

October 7th 2020

Ronan J. Kelly, MD, MBA, explains how the results of the KEYNOTE-407 trial have positioned pembrolizumab plus chemotherapy as the frontline standard of care in this setting.

Neoadjuvant Nivolumab/Chemo Combo Significantly Improves pCR in Resectable NSCLC

October 7th 2020

The combination of nivolumab plus chemotherapy resulted in a statistically significant improvement in pathologic complete response when used as neoadjuvant treatment in patients with resectable non–small cell lung cancer, meeting the primary end point of the phase 3 CheckMate-816 trial.

Dr. Gerber on the Rationale to Combine Immunotherapy With Radiation in Lung Cancer

October 2nd 2020

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.

Dr. Reck on the Safety of Pembrolizumab in KEYNOTE-024 in Metastatic NSCLC

September 30th 2020

Martin Reck, MD, PhD, discusses the safety profile observed with of pembrolizumab versus chemotherapy in patients with metastatic non–small cell lung cancer in the phase 3 KEYNOTE-024 trial.

Dissecting the Data With Immune-Based Combinations in Advanced Nonsquamous NSCLC

September 28th 2020

Jonathan Dowell, MD, discusses the data that support the use of chemoimmunotherapy in the frontline setting of nonsquamous NSCLC.

Cemiplimab Demonstrates Frontline Potential in Advanced PD-L1+ NSCLC

September 21st 2020

Cemiplimab-rwlc monotherapy led to a significant improvement in overall survival and progression-free survival versus platinum-doublet chemotherapy as first-line therapy in patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cell.

Tumor Regression Is Observed With Neoadjuvant Atezolizumab in Resectable NSCLC

September 19th 2020

One preoperative injection of atezolizumab was considered safe and induced major pathological responses in select patients with resectable non–small cell lung cancer.

EMA Recommends Approval of Nivolumab/Ipilimumab Plus Chemo in Frontline Metastatic NSCLC

September 18th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus ipilimumab with 2 cycles of platinum-based chemotherapy for the frontline treatment of patients with metastatic non–small cell lung cancer.

Dr. Chiang on the Management of Immune-Related AEs in Lung Cancer

September 10th 2020

Anne Chiang, MD, PhD, discusses the management of immune-related adverse effects in lung cancer.

ASCO 2020 Data Point to New Wave of Immunotherapy Approaches in NSCLC

September 10th 2020

David R. Spigel, MD, discusses the IMpower110, CYPRESS-1, and CANOPY-A trials, and spoke to the potential future outlook of drug development in NSCLC.

First-Line Extensive-Stage Small Cell Lung Cancer: Examining the New Role of Combination Chemotherapy and Immunotherapy

August 26th 2020

Join us to learn more about how to navigate the new role of immunotherapy in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer on Wednesday, October 28, 2020 at 8:00 PM EDT.

Nivolumab/Ipilimumab Demonstrates Durable OS Benefit in Malignant Pleural Mesothelioma

August 9th 2020

Nivolumab plus ipilimumab significantly improved overall survival versus chemotherapy in the first-line treatment of patients with unresectable malignant pleural mesothelioma.

Sintilimab/Pemetrexed Regimen Significantly Improves PFS in Advanced NSCLC

August 8th 2020

Sintilimab injection plus pemetrexed and platinum-based therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally advanced or metastatic nonsquamous non–small cell lung cancer.

Dr. Chiang on the Rationale for Chemoimmunotherapy in Lung Cancer

August 7th 2020

Anne Chiang, MD, PhD, discusses the rationale for combining immunotherapy with chemotherapy in lung cancer.

Experts Analyze Striking ASCO 2020 Data in Small Cell Lung Cancer

August 5th 2020

In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in extensive-stage SCLC and limited-stage SCLC.

Dr. Gandara on the Impact of Immunotherapy on the Tumor Microenvironment in Lung Cancer

August 3rd 2020

David R. Gandara, MD, discusses the impact of immunotherapy on the tumor microenvironment in lung cancer.

Navigating New Immune-Based Combinations in Advanced NSCLC

July 29th 2020

Joshua K. Sabari, MD, discusses a number of immunotherapy regimens that have emerged in the frontline setting for patients with driver-negative advanced non–small cell lung cancer; however, for many patients, the decision comes down to pembrolizumab monotherapy or pembrolizumab in combination with platinum-doublet chemotherapy.

Dr. Kelly on Preliminary Data With Neoadjuvant Immunotherapy in Lung Cancer

July 28th 2020

Karen Kelly, MD, discusses encouraging preliminary data with neoadjuvant immunotherapy in lung cancer.